



**HAL**  
open science

## Influence of exertional hypoxemia on cerebral oxygenation in fibrotic interstitial lung disease

Mathieu Marillier, Anne-Catherine Bernard, Samuel Verges, Onofre Moran-Mendoza, Denis E. O'donnell, J. Alberto Neder

### ► To cite this version:

Mathieu Marillier, Anne-Catherine Bernard, Samuel Verges, Onofre Moran-Mendoza, Denis E. O'donnell, et al.. Influence of exertional hypoxemia on cerebral oxygenation in fibrotic interstitial lung disease. *Respiratory Physiology & Neurobiology*, 2021, 285, pp.103601 -. 10.1016/j.resp.2020.103601 . hal-03493143

**HAL Id: hal-03493143**

**<https://hal.science/hal-03493143v1>**

Submitted on 2 Jan 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## **Influence of exertional hypoxemia on cerebral oxygenation in fibrotic interstitial lung disease**

Mathieu Marillier<sup>a,b</sup>, Anne-Catherine Bernard<sup>a,b</sup>, Samuel Verges<sup>b</sup>, Onofre Moran-Mendoza<sup>a</sup>, Denis E. O'Donnell<sup>a</sup>, J. Alberto Neder<sup>a</sup>

<sup>a</sup>Laboratory of Clinical Exercise Physiology and Respiratory Investigation Unit, Queen's University and Kingston General Hospital, Kingston, ON, Canada.

<sup>b</sup>HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.

### **Corresponding Author:**

Mathieu Marillier, PhD

76 Stuart Street, Kingston, Ontario, Canada K7L 2V7; tel: 1-613-549-6666 (ext. 3199); fax: 1-613-548-6147; e-mail: [mathieu.marillier@orange.fr](mailto:mathieu.marillier@orange.fr)

**ABSTRACT**

It is unknown whether hypoxemia, a hallmark of fibrotic interstitial lung disease (*f*-ILD), may impair cerebral oxygenation during exercise in these patients.

Twenty-seven patients [23 males, 72±8 years, lung diffusing capacity for carbon monoxide (DL<sub>CO</sub>)= 44±11% predicted] and 12 controls performed an incremental bicycle test. Prefrontal oxygenation [tissue saturation index (TSI)] was assessed by near-infrared spectroscopy.

Patients showed lower arterial O<sub>2</sub> saturation (SpO<sub>2</sub>) and larger fall in cerebral TSI during exercise *vs* controls ( $p<0.05$ ). However, changes ( $\Delta$ ) from rest to peak-exercise in SpO<sub>2</sub> (-2.2% to -26.9%) and TSI (1.4% to -16.6%) varied substantially among patients. In the 16 patients showing significant cerebral deoxygenation ( $\Delta$  TSI  $\geq 4\%$  based on controls), SpO<sub>2</sub> decreased more (-12.6±6.7% *vs* -5.7±2.8%,  $p=0.001$ ) and peak O<sub>2</sub> uptake was lower (68.3±19.2% *vs* 87.8±24.8% predicted,  $p=0.03$ ) *vs* their 11 counterparts. In association with DL<sub>CO</sub> and forced vital capacity,  $\Delta$  cerebral TSI independently predicted peak O<sub>2</sub> uptake on multivariable regression analysis ( $R^2=0.54$ ).

Exertional hypoxemia impairs cerebral oxygenation in a dose-dependent fashion in *f*-ILD. Future studies are warranted to investigate whether this potentially reversible abnormality play a contributory role in limiting exercise tolerance in these patients.

**Abstract word count: 185**

**Keywords:** exercise test; hypoxia; hypoxia, brain; pulmonary fibrosis; spectroscopy, near-infrared.

## 1. INTRODUCTION

Adequate oxygen (O<sub>2</sub>) delivery to the brain during exercise is critically dependent on cerebral blood flow (CBF) and arterial O<sub>2</sub> content (CaO<sub>2</sub>). (Smith and Ainslie, 2017) In healthy humans, impaired cerebral O<sub>2</sub> delivery has been related to the development of central fatigue i.e. a reduction in central motor output to the peripheral muscles. (Amann et al., 2007; Verges et al., 2012) The inhibition of the descending central drive is particularly relevant in the presence of severe hypoxemia (Amann et al., 2007) and may translate into increased perception of effort/fatigue upon exertion. (Amann et al., 2007; Millet et al., 2012) It follows that impaired cerebral oxygenation might contribute to poor exercise tolerance in chronic respiratory diseases associated with low CaO<sub>2</sub>. (Goodall et al., 2014a)

In this context, fibrotic interstitial lung disease (*f*-ILD) constitutes a group of disorders in which profound exercise-related hypoxemia is a cardinal feature. (Du Plessis et al., 2018) Although exercise intolerance in *f*-ILD is characteristically multifactorial [e.g. impaired pulmonary gas exchange, abnormalities in respiratory mechanics, cardio-circulatory abnormalities (Agusti et al., 1991; Faisal et al., 2016; Hansen and Wasserman, 1996)], the influence of severe hypoxemia on cerebral oxygenation during exercise in these patients is currently unknown. Several investigations previously showed that an impairment in cerebral oxygenation may contribute to a reduction in exercise tolerance in diverse chronic cardiorespiratory diseases. (Marillier et al., 2018b; Oliveira et al., 2016; Oliveira et al., 2012) Patients with *f*-

ILD may also present with limited ability of increasing cardiac output to compensate for a severely reduced  $\text{CaO}_2$ . Pulmonary micro-vasculopathy, hypoxia-induced pulmonary vasoconstriction and, as observed in some patients, overt pulmonary hypertension (Han et al., 2013; Patel et al., 2007) may hinder these compensatory haemodynamic adjustments aiming at preserving  $\text{O}_2$  delivery under these conditions. Additionally, recent findings suggest a role for exertional hypoxemia towards reduced brain perfusion and atrophy in patients with idiopathic pulmonary fibrosis. (Hett, 2019) Collectively, these premises suggest a hitherto unexplored contributory role for cerebral hypoxia in decreasing *f*-ILD patients' tolerance to dynamic exercise.

We therefore aimed to: (i) investigate the effect of exercise-related hypoxemia on cerebral oxygenation in patients with *f*-ILD and, (ii) determine whether impairment in cerebral oxygenation, when present, is associated with poorer exercise tolerance in these patients. We hypothesized that (i) increased severity of exertional hypoxemia would be associated with poorer cerebral oxygenation in patients with *f*-ILD and, (ii) impaired cerebral oxygenation would be associated with poorer exercise tolerance in this patient population.

## **2. MATERIALS AND METHODS**

**2.1. Participants.** Twenty-seven patients with well-established *f*-ILD (using clinical, physiological, high-resolution computed tomography and, in selected cases, histopathological criteria) were recruited from the Division of Respiratory's ILD clinic

(Kingston, Canada) between November 2018 to February 2020 to participate in the present prospective study. Patients were considered for study inclusion if they did not experience any ILD exacerbation requiring oral corticosteroids within the previous 3 months. Twelve healthy controls, matched for age, sex and body-mass index, were recruited from a list of sedentary subjects who had previously participated in clinical studies in our Laboratory or via advertisement. Participants refrained from intense physical activity on the two days prior to the tests and were asked to abstain from drinking caffeinated beverages on test days. This study was approved by the Queen's University Research Ethics Board (DMED-2150-18). All participants gave their written informed consent prior to their participation in the study.

**2.2. Resting procedures.** Self-reported physical activity and dyspnea burden on daily activities were assessed with the Baecke Physical Activity Questionnaire and the MRC dyspnea scale, respectively. (Baecke et al., 1982; Fletcher et al., 1959) Spirometry, static lung volumes and lung diffusing capacity for carbon monoxide ( $DL_{CO}$ ) were performed using automated equipment (Vmax229d; SensorMedics, Yorba Linda, CA). Values were compared to those predicted by specific regression equations. (Quanjer et al., 2012; Quanjer et al., 1993; Stanojevic et al., 2017)

**2.3. Incremental cardiopulmonary exercise test.** Subjects exercised on a computer-controlled electronically-braked cycle ergometer (Ergoline 800s<sup>TM</sup>; SensorMedics, Yorba Linda, CA) with breath-by-breath gas analysis and ECG measurement

(SensorMedicsVmax229d™ system). After a 3-min resting period, workload was increased by 5-15 W (according to patient's reported dyspnea burden) every 2 min until symptom limitation. Arterial O<sub>2</sub> saturation was measured continuously by earlobe pulse oximetry (SpO<sub>2</sub>; Masimo Radical 7, Masimo Corp., Irvine, CA). Participants were not required to stop exercise based on SpO<sub>2</sub> readings. Dyspnea and leg discomfort scores (0-10 category-ratio Borg scale) (Borg, 1982) and dynamic inspiratory capacity were obtained in the last 30 seconds of each stage. Reference equations for peak work rate and O<sub>2</sub> uptake were the ones from Blackie and colleagues. (Blackie et al., 1989)

**2.4. Near-infrared spectroscopy (NIRS).** Left prefrontal cortex oxy- (HbO<sub>2</sub>) and deoxyhemoglobin (HHb) concentration changes were measured throughout the testing sessions using a two-wavelength (690 and 830 nm), frequency-domain multidistance NIRS system (Imagent, ISS Inc., Champaign, IL). NIRS signal was assessed between Fp1 and F3 locations according to the international 10-20 EEG system with an interoptode distance of 2.0 to 3.5 cm. The cortical probe was secured to the skin with double-sided tape and maintained with a latex swim cap. HbO<sub>2</sub> and HHb are measured as differences from the initial rest period during the exercise test. Total haemoglobin concentration (HbTot) was calculated as the sum of HbO<sub>2</sub> and HHb. NIRS parameters reflect the dynamic balance between O<sub>2</sub> demand and supply in the tissue microcirculation: HbO<sub>2</sub> and HbTot are mostly sensitive to blood flow and O<sub>2</sub> delivery while HHb is closely associated with changes in venous O<sub>2</sub> content and therefore tissue O<sub>2</sub> extraction (Ferrari and Quaresima, 2012; Rolfe, 2000). Tissue saturation index (TSI) was calculated as the

ratio of HbO<sub>2</sub> over HbTot and is considered as a reliable estimate of change in tissue (de-)oxygenation status (Rooks et al., 2010).

**2.5. Data analysis.** Cardiorespiratory and NIRS data were averaged over the last 30 s of the resting period and over the last 30 s of each increment during exercise. Patients were categorized according to the presence of cerebral deoxygenation defined as a  $\geq 4\%$  drop in cerebral TSI during exercise. This 4% threshold was used to contrast *f*-ILD patients for cerebral deoxygenation as none of the 12 healthy subjects of similar sex, age and body-mass index (**Table 1**) showed a decrease above 3% (range: +7 to -3%) in cerebral TSI at the peak of incremental cycling in the present study.

**2.6. Statistical analysis.** All statistical procedures were performed on Statistica v.10 (Statsoft, Tulsa, OK, USA). Owing to the fact that the study's main outcome (cerebral oxygenation) has not been previously reported in fibrotic interstitial lung disease (*f*-ILD), we could not perform an "a priori" sample size calculation for the present study. Based on our sample size (N= 27 in patients with *f*-ILD, N= 12 in controls),  $\alpha=0.05$ , and considering the results provided in the manuscript i.e. changes in cerebral TSI from rest to the peak of incremental cardiopulmonary exercise testing=  $-4.7 \pm 4.2\%$  vs  $+1.7 \pm 2.8\%$  [mean difference (95% confidence intervals) =  $-6.4\%$  ( $-9.1\%$ ;  $-3.7\%$ );  $p<0.001$ ] in patients with *f*-ILD and controls, respectively, the estimated post-hoc power of the present study was however 100%. For between-group comparisons, unpaired t-test or Mann-Whitney U test were used for continuous and discrete variables, respectively.  $\chi^2$  were used to



compare frequencies. SpO<sub>2</sub> and NIRS data collected throughout exercise were analyzed by using two-way [group (healthy controls *vs* patients with *f*-ILD showing *vs* showing no significant cerebral deoxygenation) × exercise time (rest, 20%, 40%, 60%, 80%, 100% of individual exercise duration)] ANOVA. Bonferroni post-hoc tests were applied to adjust *p*-value for multiple comparisons if ANOVA revealed a statistically significant main effect or interaction. Relationships between exercise-related hypoxemia [peak-exercise SpO<sub>2</sub> and changes in SpO<sub>2</sub> from rest to peak exercise ( $\Delta$  SpO<sub>2</sub>)] and cerebral oxygenation ( $\Delta$  TSI from rest to peak exercise) and between cerebral oxygenation and exercise tolerance (peak O<sub>2</sub> uptake) in patients with *f*-ILD were evaluated by Pearson product-moment correlation and bivariate linear regression analysis. A stepwise backward multivariable regression analysis was performed to identify predictors of exercise tolerance in these patients. For all statistical analyses, a two-tailed alpha level of 0.05 was used as the cut-off for significance. Data are presented as mean  $\pm$  SD or median [interquartile range] for continuous and discrete variables, respectively.

### 3. RESULTS

#### 3.1. Participants' characteristics

Resting characteristics of healthy controls and patients with *f*-ILD are presented in **Table 1**. Healthy controls and patients with *f*-ILD had similar sex, age and body-mass index. Patients with *f*-ILD reported higher smoking history and daily dyspnea burden and lower physical activity compared to healthy controls ( $p < 0.05$ ). Lung volumes and DL<sub>CO</sub> were lower in patients with *f*-ILD compared to controls ( $p < 0.05$ ). There was no

significant difference in anthropometric characteristics, smoking history, daily dyspnea burden, self-reported physical activity and pulmonary function between patients showing (n=16) or not (n=11) cerebral deoxygenation during exercise. In addition, the prevalence of idiopathic pulmonary fibrosis was similar in patients showing (12/16; 75%) or not (8/11; 73%) cerebral deoxygenation ( $p>0.05$ ). Additional information regarding the clinical history and associated comorbidities of healthy controls and patients with *f*-ILD are provided in **Supplementary Table S1**.

### **3.2. Incremental cardiopulmonary exercise testing**

Physiological and perceptual responses at the peak of incremental cardiopulmonary exercise testing in healthy controls and patients with *f*-ILD are presented in **Table 2**. In comparison to healthy controls, patients with *f*-ILD had lower peak work rate, peak O<sub>2</sub> uptake, heart rate (% predicted) and tidal volume and higher respiratory rate, ventilatory equivalent for carbon dioxide (CO<sub>2</sub>) and ventilatory limitation ( $p<0.05$ ). They presented with lower peak-exercise SpO<sub>2</sub> and end-tidal carbon dioxide pressure and larger  $\Delta$  SpO<sub>2</sub> and  $\Delta$  cerebral TSI than controls ( $p<0.05$ ). Patients with *f*-ILD showing significant cerebral deoxygenation during exercise presented with larger exercise-related hypoxemia and lower peak O<sub>2</sub> uptake (% predicted) compared to other patients ( $p<0.05$ ). Peak work rate and O<sub>2</sub> uptake were strongly associated ( $r=0.80$ ;  $p<0.001$ ) in our sample of participants. Despite exercising at lower absolute work rates, patients with *f*-ILD had greater scores of dyspnea throughout exercise in comparison to

controls (main effect of group,  $F = 12.3$ ,  $p < 0.001$ ). Leg discomfort did not differ between groups (main effect of group,  $F = 1.4$ ,  $p = 0.25$ ; **Figure 1**).

### 3.3. Effect of exercise-related hypoxemia on cerebral oxygenation in *f*-ILD

$\Delta \text{HbO}_2$ ,  $\Delta \text{HHb}$  and  $\Delta \text{HbTot}$  as a function of exercise time during incremental cycling in healthy controls and patients with *f*-ILD are shown in **Figure 2**.  $\Delta \text{HbO}_2$  values were lower in patients with cerebral deoxygenation at 60% of exercise duration *vs* healthy controls and at 80 and 100% of exercise duration *vs* others (group  $\times$  exercise time interaction,  $F = 6.0$ ,  $p < 0.001$ ).  $\Delta \text{HHb}$  values were greater in patients showing cerebral deoxygenation at 40% of exercise duration *vs* healthy controls and at 60, 80 and 100% of exercise duration *vs* others (group  $\times$  exercise time interaction,  $F = 6.7$ ,  $p < 0.001$ ). No difference was observed between groups for  $\Delta \text{HbTot}$  ( $p > 0.05$ ).  $\Delta \text{SpO}_2$  and  $\Delta$  cerebral TSI as a function of exercise time during incremental cycling in healthy controls and patients with *f*-ILD are shown in **Figure 3**.  $\Delta \text{SpO}_2$  was larger in patients showing cerebral deoxygenation at 40% of exercise duration *vs* healthy controls and at 60, 80 and 100% of exercise duration *vs* others;  $\Delta \text{SpO}_2$  at peak was also larger in patients showing no cerebral deoxygenation *vs* healthy controls (group  $\times$  exercise time interaction,  $F = 7.3$ ,  $p < 0.001$ ).  $\Delta$  cerebral TSI at any exercise time was larger in patients showing cerebral deoxygenation *vs* others except at 20% for controls (group  $\times$  exercise time interaction,  $F = 11.4$ ,  $p < 0.001$ ).  $\Delta$  cerebral TSI was significantly associated with peak-exercise  $\text{SpO}_2$  ( $R^2 = 0.46$ ,  $r = 0.70$ ;  $p < 0.001$ ) and  $\Delta \text{SpO}_2$  ( $R^2 = 0.55$ , **Figure 4**) in patients with *f*-ILD.

### **3.4. Effect of impaired cerebral oxygenation on exercise tolerance in *f*-ILD**

Peak O<sub>2</sub> uptake (% predicted) was significantly associated with  $\Delta$  cerebral TSI ( $R^2=0.26$ , **Figure 5**) and  $\Delta$  SpO<sub>2</sub> ( $R^2=0.11$ ,  $r=0.38$ ;  $p=0.047$ ) in patients with *f*-ILD. On the other hand, peak work rate (% predicted) was not significantly associated with  $\Delta$  cerebral TSI ( $p=0.71$ ). On a multivariable regression analysis,  $\Delta$  cerebral TSI, DL<sub>CO</sub> and forced vital capacity (% predicted), independently predicted peak O<sub>2</sub> uptake (% predicted) (**Table 3**).

## **4. DISCUSSION**

The present study is the first to investigate the influence of hypoxemia on cerebral oxygenation during physical exertion and its consequences on exercise tolerance in patients with *f*-ILD. We found that i) exertional hypoxemia was associated with impaired cerebral oxygenation in a dose-dependent fashion in patients with *f*-ILD and, ii) impairment in cerebral oxygenation was an independent predictor of poor exercise tolerance in this patient population. These findings indicate that profound exercise-related hypoxemia, a cardinal feature of *f*-ILD, may impair cerebral oxygenation, which, in turn, may contribute to decreasing exercise tolerance in these patients. The latter assertion, however, requires further investigation in interventional studies offering measurements of central fatigue.

### **4.1. Influence of hypoxemia on cerebral oxygenation during exercise**

Impaired cerebral oxygenation is a consistent finding in healthy individuals exercising in hypoxia or at high altitude. (Marillier et al., 2020b; Rupp and Perrey, 2009; Subudhi et al., 2009) Although some studies reported an increase in CBF (Goodall et al., 2014b; Rasmussen et al., 2010; Subudhi et al., 2009) to compensate for a reduced  $\text{CaO}_2$ , cerebral  $\text{O}_2$  delivery and oxygenation during exercise in hypoxia were found to be reduced (Goodall et al., 2012; Goodall et al., 2014b). This reduction in cerebral  $\text{O}_2$  delivery may hold particularly true at high intensity of exercise in hypoxia and potentially constitute a signal to limit exercise capacity under such conditions (Vogiatzis et al., 2011). In chronic cardiorespiratory diseases, exercise-related hypoxemia has also been related to a poorer cerebral oxygenation. (Oliveira et al., 2016; Oliveira et al., 2012) For instance, diverging patterns of cerebral oxygenation were observed in patients with chronic obstructive pulmonary disease with or without exercise-induced  $\text{O}_2$  desaturation in response to incremental cycling. (Oliveira et al., 2012) The severity of exertional hypoxemia in *f*-ILD, however, finds no parallel in respiratory medicine. (Du Plessis et al., 2018) A major advantage of the present study is the large variability in the extent of exercise-related hypoxemia experienced by patients with *f*-ILD to explore its effect on cerebral oxygenation (**Figure 3 and 4**). In fact, we found that exercise-related hypoxemia on its own explained ~50% of the variance in cerebral oxygenation on exertion (**Figure 4**). In this context, the remaining inter-individual variability in cerebral deoxygenation during exercise might be explained by other factors such as changes in CBF or cerebral metabolism. (Smith and Ainslie, 2017) Our data rather suggest that impairment in cerebral oxygenation in *f*-ILD may mostly be secondary to a low  $\text{CaO}_2$  (i.e. an altered

balance between HbO<sub>2</sub> and HHb) rather than impaired CBF since similar HbTot (a surrogate of CBF) kinetics were observed during exercise in our 3 groups (**Figure 2**). Further studies providing comprehensive measurement of cerebral hemodynamics in *f*-ILD are yet warranted to confirm this assumption.

Patients with *f*-ILD presenting with mild to moderately-severe exercise-related hypoxemia (peak-exercise SpO<sub>2</sub>= 85-94% (Dempsey and Wagner, 1999)) had preserved cerebral oxygenation in two thirds of cases (**Figure 4**). Different compensatory mechanisms aiming at preserving cerebral oxygenation under low levels of CaO<sub>2</sub> may have been brought into play. (Smith and Ainslie, 2017) Arterial blood gases (CO<sub>2</sub> in particular) have a major influence on CBF during exercise. (Smith and Ainslie, 2017) CBF increases as arterial partial pressure of O<sub>2</sub> falls below 60 mmHg (Ogoh et al., 2013) (SpO<sub>2</sub> ~90% (Madan, 2017)). In fact, a 0.5-2.5% increase in CBF typically occurs for each % reduction in SpO<sub>2</sub>. (Hoiland et al., 2016) Milder decline in SpO<sub>2</sub>, leading to a lesser increase in hypoxia-induced hyperventilation, may also prevent large drop in arterial partial pressure of CO<sub>2</sub>. (Hoiland et al., 2018) This may help maintain greater CBF as any reduction of 1 mmHg in CO<sub>2</sub> levels has been associated with a 1-3% decrease in brain perfusion. (Willie et al., 2014) In the present study, we found no difference in end-tidal carbon dioxide pressure during exercise in patients showing significant cerebral deoxygenation and their counterparts (**Table 2**) and no association between end-tidal carbon dioxide pressure and  $\Delta$  TSI or HbTot (an index of CBF) at peak exercise (data not shown). It is noteworthy that, however, end-tidal carbon dioxide pressure may poorly reflect arterial partial pressure of CO<sub>2</sub> in this population due to significant ventilation-

perfusion mismatch. In patients in whom exercise-related hypoxemia further intensified (peak-exercise  $\text{SpO}_2 < 85\%$ ), cerebral oxygenation was systemically compromised (**Figure 4**). Oxygen therapy is commonly prescribed for patients with *f*-ILD although there is currently limited evidence supporting its clinical benefits (Khor et al., 2017); this may hold particularly true in case of isolated exertional hypoxemia (Johannson et al., 2017). Interestingly, exertional  $\text{SpO}_2 < 85\%$  coincides with a recent experts' consensus in which this threshold was established to recommend supplemental  $\text{O}_2$  therapy in these patients with *f*-ILD. (Lim et al., 2019) Supplemental  $\text{O}_2$  therapy may, therefore, be prescribed not only to help alleviate symptoms (e.g. dyspnea or cough) and functional impairment attributable to hypoxemia as proposed in this document (Lim et al., 2019) but also to preserve  $\text{O}_2$  delivery to the organ the most in need: the brain.

#### **4.2. Physiological consequences of impaired cerebral oxygenation**

In the present study, patients with *f*-ILD showing significant cerebral deoxygenation during exercise (a priori defined as a  $\geq 4\%$  drop in cerebral TSI based on our sample of healthy matched controls) presented with greater exercise-related hypoxemia and poorer tolerance to physical exertion (peak  $\text{O}_2$  uptake % predicted) compared to other patients (**Table 2**). In fact, larger cerebral deoxygenation was independently associated with a lower tolerance to exercise in our population (**Table 3**). Interestingly, exercise-related hypoxemia was not identified as an independent predictor of exercise tolerance:

monitoring cerebral oxygenation, in addition to systemic oxygenation, may therefore be of particular interest in a clinical setting in *f*-ILD.

In patients with *f*-ILD showing mild to moderately-severe exertional hypoxemia, an impairment of the descending motor drive to the exercising muscles, the so-called central fatigue (Verges et al., 2012), may have arisen from a heightened stimulation of peripheral muscles' afferences (Amann et al., 2009): poorer O<sub>2</sub> delivery to the working muscles, due to a low CaO<sub>2</sub>, has been associated with disturbance in muscle metabolic milieu (Allen et al., 2008). However, in the context of severe hypoxemia, a marked reduction in cerebral oxygenation may promote an impairment of the descending motor drive independently of muscle afferences during exercise. (Goodall et al., 2014a) It follows that impaired cerebral oxygenation, and, consequently, central fatigue are typically considered as major contributors to exercise limitation when SpO<sub>2</sub> ≤75%. (Goodall et al., 2014a; Verges et al., 2012) Interestingly, almost 50% of *f*-ILD patients showing significant cerebral deoxygenation presented with peak-exercise SpO<sub>2</sub> ≤80%. While alterations in respiratory mechanics and cardio-circulatory abnormalities typically assume a prominent role in impeding exercise tolerance in patients with *f*-ILD (Agusti et al., 1991; Faisal et al., 2016; Hansen and Wasserman, 1996), the intensified severity of cerebral hypoxia may have been a pivotal mechanism in this subset of patients. Yet, this assumption remains to be confirmed since, for instance, supplemental O<sub>2</sub> (fraction of inspired O<sub>2</sub>= 1.0) or heliox prolonged endurance time in patients with chronic obstructive pulmonary disease despite similar cerebral cortex O<sub>2</sub> delivery compared to room air, suggesting that an improvement in cerebral cortex O<sub>2</sub> availability



does not hold a contributing role in enhancing exercise capacity in these patients (Vogiatzis et al., 2013). Of note, chronic hypoxemia has been related to a lower supraspinal motor drive objectively assessed with neurostimulation techniques and, consequently, poorer exercise performance in other respiratory disorders. (Alexandre et al., 2016; Marillier et al., 2018a)

Beyond its contribution to exercise intolerance, repeated bouts of cerebral hypoxia during daily life physical activity might have additional deleterious physiological consequences in *f*-ILD. Recurrent exposure to cerebral hypoxia, in combination with an increased prevalence of atherosclerosis observed in elderly individuals (Uryga and Bennett, 2016) might enhance the risk of ischemic stroke in *f*-ILD. In fact, intermittent hypoxia (hypothetically experienced if alternating phases of exercise and rest) has been shown to increase the occurrence of stroke due to endothelial dysfunction. (Beaudin et al., 2017) It is also conceivable that long-term exposure to cerebral hypoxia might lead to negative cognitive outcomes in patients with *f*-ILD. For instance, chronic exposure to intermittent hypoxia secondary to upper airway obstruction in sleep apnea has been related to brain structural alterations. (Rosenzweig et al., 2015) These structural impairments may illustrate cognitive disorders (memory, attention, learning and executive function (Bucks et al., 2017)) typically observed in these patients. (Rosenzweig et al., 2015) Seminal findings have recently suggested a role for exertional hypoxemia towards reduced brain perfusion and atrophy in patients with idiopathic pulmonary fibrosis. (Hett, 2019) Yet, the implication of these results in terms of cerebrovascular events and cognitive outcomes remains to be investigated in *f*-ILD.

### 4.3. Limitations and perspectives

NIRS is only suitable for investigating cerebral hemodynamics in structures that are not deeper than approximately 2–3 cm below the surface of the brain (Perrey, 2008). It also allows the investigation of restricted brain areas (e.g. prefrontal cortex). However, this cerebral region may be of particular interest: the role of the prefrontal cortex in exercise tolerance and termination has been recently emphasized (Robertson and Marino, 2016). In fact, the prefrontal cortex is involved in motivational and decision-making processes and may act as a relay station in the central fatigue related network regulating central command through peripheral feedback (Perrey, 2015). Moreover, assessing this brain area may be of further interest due to its implication in different cognitive processes (i.e. executive function, attention and memory) (Miller and Cohen, 2001). Comprehensive measurement of CBF (e.g. using transcranial Doppler) and the influence of arterial blood gases on brain perfusion would provide additional insights into cerebral hemodynamics during exercise in patients with *f*-ILD. Patients with respiratory disorders typically avoid strenuous physical activity (Guthrie et al., 2001), which might dampen the translation of our results in daily life. Yet, larger exercise-induced hypoxemia (owing to a larger muscle mass and, therefore, greater O<sub>2</sub> extraction) is usually found in response to walking compared to cycling. This might translate into larger cerebral deoxygenation in patients with *f*-ILD. Although exercise-induced hypoxemia has been shown to impair muscle oxygenation and exacerbate peripheral muscle fatigue in patients with *f*-ILD (Marillier et al., 2020a), our assumptions relating

impaired cerebral oxygenation to the subsequent development of central fatigue are of inferential nature. Future research using neurostimulation techniques to objectively assess central/supraspinal mechanisms of fatigue (e.g. transcranial magnetic stimulation (Marillier et al., 2017)) and intervention (e.g. O<sub>2</sub> supplementation) in this population would help confirm this hypothesis. Such investigations may help identify patients in whom impaired cerebral O<sub>2</sub> delivery assume a prominent role in exercise limitation due to exaggerated neuromuscular fatigue.

#### 4.4. Conclusion

The present study innovates by investigating the influence of exertional hypoxemia on cerebral oxygenation and its consequences on exercise tolerance in patients with *f*-ILD. Our main findings indicate that exertional hypoxemia does impair cerebral oxygenation in a dose-dependent fashion in these patients, being independently related to exercise capacity. Reversing cerebral hypoxia with O<sub>2</sub> supplementation may have positive effects on patients' disablement beyond those expected from lower ventilation and **dyspnea**, an issue that deserves further investigation.

## ACKNOWLEDGEMENTS

The authors thank the members of the Respiratory Investigation Unit (Queen's University), Angie Zapotichny, Filipa Saramago and Brandon Palmer (Kingston Health Sciences Centre) for their continuous assistance.

**Author contribution:** MM and ACB collected and analyzed the data. MM, ACB, SV, OMM, DOD and JAN were all involved in the interpretation of the results. MM drafted the first version of the manuscript and all authors provided critical feedback to shape the final version of the manuscript. All authors approved the final version of the manuscript to be published and agree to be accountable for all aspects of the present work.

**Declarations of interest:** MM was a recipient of a Long-Term Research Fellowship (LTRF 2018) from the European Respiratory Society to support his postdoctoral fellowship at Queen's University. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.

## REFERENCES

- Agusti, A.G., Roca, J., Gea, J., Wagner, P.D., Xaubet, A., Rodriguez-Roisin, R., 1991. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. *Am Rev Respir Dis* 143, 219-225.
- Alexandre, F., Heraud, N., Sanchez, A.M., Tremey, E., Oliver, N., Guerin, P., Varray, A., 2016. Brain Damage and Motor Cortex Impairment in Chronic Obstructive Pulmonary Disease: Implication of Nonrapid Eye Movement Sleep Desaturation. *Sleep* 39, 327-335.
- Allen, D.G., Lamb, G.D., Westerblad, H., 2008. Skeletal muscle fatigue: cellular mechanisms. *Physiol Rev* 88, 287-332.
- Amann, M., Proctor, L.T., Sebranek, J.J., Pegelow, D.F., Dempsey, J.A., 2009. Opioid-mediated muscle afferents inhibit central motor drive and limit peripheral muscle fatigue development in humans. *J Physiol* 587, 271-283.
- Amann, M., Romer, L.M., Subudhi, A.W., Pegelow, D.F., Dempsey, J.A., 2007. Severity of arterial hypoxaemia affects the relative contributions of peripheral muscle fatigue to exercise performance in healthy humans. *J Physiol* 581, 389-403.
- Baecke, J.A., Burema, J., Frijters, J.E., 1982. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 36, 936-942.
- Beaudin, A.E., Waltz, X., Hanly, P.J., Poulin, M.J., 2017. Impact of obstructive sleep apnoea and intermittent hypoxia on cardiovascular and cerebrovascular regulation. *Exp Physiol* 102, 743-763.
- Blackie, S.P., Fairbairn, M.S., McElvaney, G.N., Morrison, N.J., Wilcox, P.G., Pardy, R.L., 1989. Prediction of maximal oxygen uptake and power during cycle ergometry in subjects older than 55 years of age. *Am Rev Respir Dis* 139, 1424-1429.
- Borg, G., (1982). A category scale with ratio properties for intermodal and interindividual comparisons, in: Geissler, H.G., Petzold, P. (Eds.), *Psychophysical judgment and the process of perception*. Amsterdam: VEB Deutscher Verlag der Wissenschaften, pp. 25-34.
- Bucks, R.S., Olaithe, M., Rosenzweig, I., Morrell, M.J., 2017. Reviewing the relationship between OSA and cognition: Where do we go from here? *Respirology* 22, 1253-1261.

- Dempsey, J.A., Wagner, P.D., 1999. Exercise-induced arterial hypoxemia. *J Appl Physiol* (1985) 87, 1997-2006.
- Du Plessis, J.P., Fernandes, S., Jamal, R., Camp, P., Johannson, K., Schaeffer, M., Wilcox, P.G., Guenette, J.A., Ryerson, C.J., 2018. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. *Respirology* 23, 392-398.
- Faisal, A., Alghamdi, B.J., Ciavaglia, C.E., Elbehairy, A.F., Webb, K.A., Ora, J., Neder, J.A., O'Donnell, D.E., 2016. Common Mechanisms of Dyspnea in Chronic Interstitial and Obstructive Lung Disorders. *Am J Respir Crit Care Med* 193, 299-309.
- Ferrari, M., Quaresima, V., 2012. A brief review on the history of human functional near-infrared spectroscopy (fNIRS) development and fields of application. *Neuroimage* 63, 921-935.
- Fletcher, C.M., Elmes, P.C., Fairbairn, A.S., Wood, C.H., 1959. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. *Br Med J* 2, 257-266.
- Goodall, S., Gonzalez-Alonso, J., Ali, L., Ross, E.Z., Romer, L.M., 2012. Supraspinal fatigue after normoxic and hypoxic exercise in humans. *J Physiol* 590, 2767-2782.
- Goodall, S., Twomey, R., Amann, M., 2014a. Acute and chronic hypoxia: implications for cerebral function and exercise tolerance. *Fatigue* 2, 73-92.
- Goodall, S., Twomey, R., Amann, M., Ross, E.Z., Lovering, A.T., Romer, L.M., Subudhi, A.W., Roach, R.C., 2014b. AltitudeOmics: exercise-induced supraspinal fatigue is attenuated in healthy humans after acclimatization to high altitude. *Acta Physiol (Oxf)* 210, 875-888.
- Guthrie, S.J., Hill, K.M., Muers, M.E., 2001. Living with severe COPD. A qualitative exploration of the experience of patients in Leeds. *Respir Med* 95, 196-204.
- Han, M.K., Bach, D.S., Hagan, P.G., Yow, E., Flaherty, K.R., Toews, G.B., Anstrom, K.J., Martinez, F.J., Investigators, I.P., 2013. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. *Chest* 143, 1699-1708.

- Hansen, J.E., Wasserman, K., 1996. Pathophysiology of activity limitation in patients with interstitial lung disease. *Chest* 109, 1566-1576.
- Hett, K.L.P., E.; Chandler, H.; Hope-Gill, B.D.M.; Wise, R.G., (2019). Evaluating brain structure and cerebrovascular function in idiopathic pulmonary fibrosis using MRI, British Thoracic Society Winter Meeting 2019. Thorax, London.
- Hoiland, R.L., Bain, A.R., Rieger, M.G., Bailey, D.M., Ainslie, P.N., 2016. Hypoxemia, oxygen content, and the regulation of cerebral blood flow. *Am J Physiol Regul Integr Comp Physiol* 310, R398-413.
- Hoiland, R.L., Howe, C.A., Coombs, G.B., Ainslie, P.N., 2018. Ventilatory and cerebrovascular regulation and integration at high-altitude. *Clin Auton Res* 28, 423-435.
- Johannson, K.A., Pendharkar, S.R., Mathison, K., Fell, C.D., Guenette, J.A., Kalluri, M., Kolb, M., Ryerson, C.J., 2017. Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. *Ann Am Thorac Soc* 14, 1373-1377.
- Khor, Y.H., Goh, N.S.L., McDonald, C.F., Holland, A.E., 2017. Oxygen Therapy for Interstitial Lung Disease: Physicians' Perceptions and Experiences. *Ann Am Thorac Soc* 14, 1772-1778.
- Lim, R.K., Humphreys, C., Morisset, J., Holland, A.E., Johannson, K.A., and the, O.D.C., 2019. Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. *Eur Respir J* 54.
- Madan, A., 2017. Correlation between the levels of SpO<sub>2</sub> and PaO<sub>2</sub>. *Lung India* 34, 307-308.
- Marillier, M., Arnal, P.J., Le Roux Mallouf, T., Rupp, T., Millet, G.Y., Verges, S., 2017. Effects of high-altitude exposure on supraspinal fatigue and corticospinal excitability and inhibition. *Eur J Appl Physiol* 117, 1747-1761.
- Marillier, M., Bernard, A.C., Moran-Mendoza, O., O'Donnell, D.E., Verges, S., Neder, J.A., (2020a). Beyond the lungs in fibrotic interstitial lung disease: does supplemental O<sub>2</sub> improve skeletal muscle oxygenation and fatigue?, European Respiratory Society International Congress. *European Respiratory Journal*.

- Marillier, M., Gruet, M., Baillieul, S., T, L.E.R.M., Wuyam, B., Tamsier, R., Levy, P., Pepin, J.L., Verges, S., 2018a. Neuromuscular Dysfunction and Cortical Impairment in Sleep Apnea Syndrome. *Med Sci Sports Exerc* 50, 1529-1539.
- Marillier, M., Gruet, M., Baillieul, S., Wuyam, B., Tamsier, R., Levy, P., Pepin, J.L., Verges, S., 2018b. Impaired cerebral oxygenation and exercise tolerance in patients with severe obstructive sleep apnea syndrome. *Sleep Med* 51, 37-46.
- Marillier, M., Rupp, T., Bouzat, P., Walther, G., Baillieul, S., Millet, G.Y., Robach, P., Verges, S., 2020b. Cerebral haemodynamics and oxygenation during whole-body exercise over 5 days at high altitude. *Exp Physiol*.
- Miller, E.K., Cohen, J.D., 2001. An integrative theory of prefrontal cortex function. *Annu Rev Neurosci* 24, 167-202.
- Millet, G.Y., Muthalib, M., Jubeau, M., Laursen, P.B., Nosaka, K., 2012. Severe hypoxia affects exercise performance independently of afferent feedback and peripheral fatigue. *J Appl Physiol* (1985) 112, 1335-1344.
- Ogoh, S., Sato, K., Nakahara, H., Okazaki, K., Subudhi, A.W., Miyamoto, T., 2013. Effect of acute hypoxia on blood flow in vertebral and internal carotid arteries. *Exp Physiol* 98, 692-698.
- Oliveira, M.F., Alencar, M.C., Arbex, F., Souza, A., Sperandio, P., Medina, L., Medeiros, W.M., Hirai, D.M., O'Donnell, D.E., Neder, J.A., 2016. Effects of heart failure on cerebral blood flow in COPD: Rest and exercise. *Respir Physiol Neurobiol* 221, 41-48.
- Oliveira, M.F., Rodrigues, M.K., Treptow, E., Cunha, T.M., Ferreira, E.M., Neder, J.A., 2012. Effects of oxygen supplementation on cerebral oxygenation during exercise in chronic obstructive pulmonary disease patients not entitled to long-term oxygen therapy. *Clin Physiol Funct Imaging* 32, 52-58.
- Patel, N.M., Lederer, D.J., Borczuk, A.C., Kawut, S.M., 2007. Pulmonary hypertension in idiopathic pulmonary fibrosis. *Chest* 132, 998-1006.
- Perrey, S., 2008. Non-invasive NIR spectroscopy of human brain function during exercise. *Methods* 45, 289-299.



- Perrey, S., 2015. Editorial: Investigating the human brain and muscle coupling during whole-body challenging exercise. *Front Physiol* 6, 285.
- Quanjer, P.H., Stanojevic, S., Cole, T.J., Baur, X., Hall, G.L., Culver, B.H., Enright, P.L., Hankinson, J.L., Ip, M.S., Zheng, J., Stocks, J., Initiative, E.R.S.G.L.F., 2012. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 40, 1324-1343.
- Quanjer, P.H., Tammeling, G.J., Cotes, J.E., Pedersen, O.F., Peslin, R., Yernault, J.C., 1993. Lung volumes and forced ventilatory flows. *Eur Respir J* 6 Suppl 16, 5-40.
- Rasmussen, P., Nielsen, J., Overgaard, M., Krogh-Madsen, R., Gjedde, A., Secher, N.H., Petersen, N.C., 2010. Reduced muscle activation during exercise related to brain oxygenation and metabolism in humans. *J Physiol* 588, 1985-1995.
- Robertson, C.V., Marino, F.E., 2016. A role for the prefrontal cortex in exercise tolerance and termination. *J Appl Physiol* (1985) 120, 464-466.
- Rolfe, P., 2000. In vivo near-infrared spectroscopy. *Annu Rev Biomed Eng* 2, 715-754.
- Rooks, C.R., Thom, N.J., McCully, K.K., Dishman, R.K., 2010. Effects of incremental exercise on cerebral oxygenation measured by near-infrared spectroscopy: a systematic review. *Prog Neurobiol* 92, 134-150.
- Rosenzweig, I., Glasser, M., Polsek, D., Leschziner, G.D., Williams, S.C., Morrell, M.J., 2015. Sleep apnoea and the brain: a complex relationship. *Lancet Respir Med* 3, 404-414.
- Rupp, T., Perrey, S., 2009. Effect of severe hypoxia on prefrontal cortex and muscle oxygenation responses at rest and during exhaustive exercise. *Adv Exp Med Biol* 645, 329-334.
- Smith, K.J., Ainslie, P.N., 2017. Regulation of cerebral blood flow and metabolism during exercise. *Exp Physiol* 102, 1356-1371.
- Stanojevic, S., Graham, B.L., Cooper, B.G., Thompson, B.R., Carter, K.W., Francis, R.W., Hall, G.L., Global Lung Function Initiative, T.w.g., Global Lung Function Initiative, T., 2017. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. *Eur Respir J* 50.

- Subudhi, A.W., Miramon, B.R., Granger, M.E., Roach, R.C., 2009. Frontal and motor cortex oxygenation during maximal exercise in normoxia and hypoxia. *J Appl Physiol* (1985) 106, 1153-1158.
- Uryga, A.K., Bennett, M.R., 2016. Ageing induced vascular smooth muscle cell senescence in atherosclerosis. *J Physiol* 594, 2115-2124.
- Verges, S., Rupp, T., Jubeau, M., Wuyam, B., Esteve, F., Levy, P., Perrey, S., Millet, G.Y., 2012. Cerebral perturbations during exercise in hypoxia. *Am J Physiol Regul Integr Comp Physiol* 302, R903-916.
- Vogiatzis, I., Louvaris, Z., Habazettl, H., Andrianopoulos, V., Wagner, H., Roussos, C., Wagner, P.D., Zakyntinos, S., 2013. Cerebral cortex oxygen delivery and exercise limitation in patients with COPD. *Eur Respir J* 41, 295-301.
- Vogiatzis, I., Louvaris, Z., Habazettl, H., Athanasopoulos, D., Andrianopoulos, V., Cherouveim, E., Wagner, H., Roussos, C., Wagner, P.D., Zakyntinos, S., 2011. Frontal cerebral cortex blood flow, oxygen delivery and oxygenation during normoxic and hypoxic exercise in athletes. *J Physiol* 589, 4027-4039.
- Willie, C.K., Tzeng, Y.C., Fisher, J.A., Ainslie, P.N., 2014. Integrative regulation of human brain blood flow. *J Physiol* 592, 841-859.

**Table 1.** Resting characteristics of healthy controls and patients with *f*-ILD. Patients were categorized by the presence (+) or not (-) of cerebral deoxygenation during incremental cardiopulmonary exercise testing.

|  | Controls (n=12) | <i>f</i> -ILD       |                                   |                                   |
|--|-----------------|---------------------|-----------------------------------|-----------------------------------|
|  |                 | All patients (n=27) | (-) Cerebral deoxygenation (n=11) | (+) Cerebral deoxygenation (n=16) |
| Sex  | 9 ♂ / 3 ♀       | 23 ♂ / 4 ♀          | 10 ♂ / 1 ♀                        | 13 ♂ / 3 ♀                        |
| Age (years)                                | 73.3 ± 8.9      | 71.6 ± 8.1          | 74.6 ± 7.1                        | 69.6 ± 8.4                        |
| BMI (kg m <sup>-2</sup> )                  | 27.3 ± 3.2      | 28.3 ± 3.5          | 28.7 ± 3.9                        | 28.0 ± 3.3                        |
| Smoking history (pack year <sup>-1</sup> ) | 2 ± 4           | 21 ± 18 *           | 23 ± 21                           | 19 ± 16                           |
| <b>Questionnaires</b>                      |                 |                     |                                   |                                   |
| MRC  | 1.0 [0.0]       | 2.0 [1.0] *         | 2.0 [1.0]                         | 3.0 [2.0]                         |
| Baecke                                     | 7.9 [1.1]       | 7.3 [1.6] *         | 6.6 [1.9]                         | 7.3 [1.3]                         |
| <b>Pulmonary function</b>                  |                 |                     |                                   |                                   |
| FEV <sub>1</sub> (% pred)                  | 99.1 ± 16.6     | 73.6 ± 15.5 *       | 78.7 ± 16.9                       | 70.1 ± 14.0                       |
| FVC (% pred)                               | 107.1 ± 13.9    | 75.9 ± 20.2 *       | 79.6 ± 22.5                       | 73.4 ± 18.8                       |
| FEV <sub>1</sub> /FVC (%)                  | 71.0 ± 7.2      | 75.6 ± 10.2         | 76.5 ± 9.4                        | 74.9 ± 10.9                       |
| TLC (% pred)                               | 98.5 ± 11.2     | 65.3 ± 15.0 *       | 67.6 ± 15.0                       | 63.6 ± 15.3                       |
| RV (% pred)                                | 87.3 ± 20.8     | 49.5 ± 15.1 *       | 50.4 ± 9.6                        | 48.9 ± 18.2                       |
| FRC (% pred)                               | 90.1 ± 15.1     | 61.2 ± 16.4 *       | 60.7 ± 17.2                       | 61.5 ± 16.4                       |
| IC (% pred)                                | 108.4 ± 18.4    | 79.1 ± 20.9 *       | 86.7 ± 19.6                       | 73.9 ± 20.8                       |
| DL <sub>CO</sub> (% pred)                  | 91.7 ± 16.9     | 43.5 ± 10.7 *       | 47.8 ± 10.0                       | 40.5 ± 10.5                       |

Data are mean ± SD or median [interquartile range]. BMI: body mass index; DL<sub>CO</sub>: lung diffusing capacity for carbon monoxide; FEV<sub>1</sub>: forced expiratory volume in one second; FRC: functional residual capacity; FVC: forced vital capacity; IC: inspiratory capacity; *f*-ILD: fibrotic interstitial lung disease; MRC: Medical Research Council; RV: residual volume; TLC: total lung capacity. \* *p*<0.05: patients with *f*-ILD vs healthy controls.

**Table 2.** Physiological and perceptual responses of healthy controls and patients with *f*-ILD at the peak of cardiopulmonary exercise testing. Patients were categorized by the presence (+) or not (-) of cerebral deoxygenation during cardiopulmonary exercise testing.

|  | Controls (n=12) | <i>f</i> -ILD       |                                   |                                   |
|--|-----------------|---------------------|-----------------------------------|-----------------------------------|
|  |                 | All patients (n=27) | (-) Cerebral deoxygenation (n=11) | (+) Cerebral deoxygenation (n=16) |
| <b>Power/Metabolic/cardiovascular</b>        |                 |                     |                                   |                                   |
| Work rate (W)                                | 109.8 ± 20.7    | 75.3 ± 22.7 *       | 82.1 ± 16.0                       | 70.6 ± 25.8                       |
| Work rate (% pred)                           | 80.6 ± 21.4     | 53.9 ± 13.8 *       | 56.4 ± 10.7                       | 52.1 ± 15.7                       |
| VO <sub>2</sub> (mL · kg min <sup>-1</sup> ) | 21.5 ± 4.1      | 14.9 ± 3.6 *        | 15.9 ± 3.1                        | 14.3 ± 3.9                        |
| VO <sub>2</sub> (% pred)                     | 110.0 ± 30.8    | 76.3 ± 23.3 *       | 87.8 ± 24.8                       | 68.3 ± 19.2 †                     |
| HR (bpm)                                     | 137.6 ± 16.7    | 125.1 ± 19.5        | 128.3 ± 20.4                      | 123.0 ± 19.3                      |
| HR (% pred)                                  | 94.0 ± 11.8     | 84.3 ± 12.7 *       | 88.2 ± 14.0                       | 81.6 ± 11.3                       |
| <b>Ventilatory</b>                           |                 |                     |                                   |                                   |
| V <sub>E</sub> (L)                           | 67.0 ± 17.1     | 61.8 ± 16.0         | 64.0 ± 18.2                       | 60.3 ± 14.8                       |
| V <sub>E</sub> /VCO <sub>2</sub>             | 33.0 ± 4.3      | 43.2 ± 7.8 *        | 41.2 ± 6.5                        | 44.6 ± 8.5                        |
| V <sub>T</sub> /IC (%)                       | 72.2 ± 13.6     | 85.2 ± 15.7 *       | 83.6 ± 13.1                       | 86.4 ± 17.5                       |
| V <sub>E</sub> /MVV (%)                      | 71.6 ± 22.4     | 87.4 ± 22.2 *       | 84.7 ± 24.0                       | 89.2 ± 21.4                       |
| V <sub>T</sub> (L)                           | 2.07 ± 0.42     | 1.54 ± 0.43 *       | 1.69 ± 0.40                       | 1.44 ± 0.44                       |
| RR (breaths min <sup>-1</sup> )              | 32.9 ± 5.5      | 41.8 ± 10.9 *       | 39.3 ± 12.4                       | 43.6 ± 9.7                        |
| <b>Pulmonary gas exchange</b>                |                 |                     |                                   |                                   |
| SpO <sub>2</sub> (%)                         | 97.3 ± 0.6      | 85.2 ± 7.7 *        | 90.4 ± 3.0                        | 81.7 ± 8.0 †                      |
| Δ SpO <sub>2</sub> (%)                       | -0.3 ± 1.0      | -9.8 ± 6.4 *        | -5.7 ± 2.8                        | -12.6 ± 6.7 †                     |
| PETCO <sub>2</sub> (mmHg)                    | 35.1 ± 3.9      | 30.8 ± 4.1 *        | 31.2 ± 4.7                        | 30.5 ± 3.8                        |
| <b>Cerebral oxygenation</b>                  |                 |                     |                                   |                                   |
| Δ TSI (%)                                    | 1.7 ± 2.8       | -4.7 ± 4.2 *        | -0.8 ± 1.4                        | -7.4 ± 3.3 †                      |
| <b>Symptoms</b>                              |                 |                     |                                   |                                   |
| Dyspnea/work rate                            | 0.034 [0.018]   | 0.057 [0.031] *     | 0.054 [0.009]                     | 0.063 [0.045]                     |
| Leg discomfort/work rate                     | 0.045 [0.026]   | 0.058 [0.040]       | 0.068 [0.035]                     | 0.048 [0.046]                     |

Data are mean ± SD or median [interquartile range]. HR: heart rate; IC: inspiratory capacity; *f*-ILD: fibrotic interstitial lung disease; MVV: maximal voluntary ventilation; PETCO<sub>2</sub>: end-tidal carbon dioxide pressure; RR: respiratory rate; SpO<sub>2</sub>: oxygen saturation by

pulse oximetry;  $\Delta \text{SpO}_2$ : difference between peak and resting oxygen saturation values;  $\text{VCO}_2$ : carbon dioxide output;  $\text{V}_E$ : minute ventilation;  $\text{V}_E/\text{VCO}_2$ : ventilatory equivalent for  $\text{CO}_2$ ;  $\text{VO}_2$ : oxygen uptake;  $\text{V}_T$ : tidal volume;  $\Delta \text{TSI}$ : difference between peak and resting values in cerebral tissue saturation index. \*  $p < 0.05$  : patients with *f*-ILD *vs* healthy controls. †  $p < 0.05$  : patients with *f*-ILD showing *vs* showing no cerebral deoxygenation.

**Table 3.** Stepwise backward multivariable regression analysis to predict exercise

| Independent predictors         | B      | 95% confidence interval | <i>p</i> | Adjusted R <sup>2</sup> |
|--------------------------------|--------|-------------------------|----------|-------------------------|
| DL <sub>CO</sub> (% predicted) | 0.804  | 0.149–1.459             | 0.018    | 0.538                   |
| Δ TSI (%)                      | 1.916  | 0.297–3.534             | 0.022    |                         |
| FVC (% predicted)              | 0.385  | 0.039–0.732             | 0.031    |                         |
| Constant                       | 21.048 | -15.139–57.234          |          |                         |

tolerance (peak O<sub>2</sub> uptake, % predicted) in patients with fibrotic interstitial lung disease.

In addition to lung diffusing capacity for carbon monoxide (DL<sub>CO</sub>), difference between peak and resting values in cerebral tissue saturation index (Δ TSI) and forced vital capacity (FVC), variables initially considered in the multivariable model were: total lung capacity (% predicted), inspiratory capacity (% predicted), peak exercise O<sub>2</sub> saturation by pulse oximetry (SpO<sub>2</sub>, %), difference between peak and resting values in SpO<sub>2</sub> (Δ SpO<sub>2</sub>, %), peak exercise tidal volume/inspiratory capacity and minute ventilation/maximal voluntary ventilation ratios and ventilatory equivalent for carbon dioxide nadir.

## FIGURE LEGENDS

**Figure 1.** Scores of dyspnea (panel a) and leg discomfort (panel b) as a function of exercise time during incremental cycling in healthy controls and patients with fibrotic interstitial lung disease (*f*-ILD) who presented (+) or not (-) with significant cerebral deoxygenation.

Data are mean  $\pm$  SD and are slightly shifted at each exercise time to avoid overlap. \*  $p < 0.05$  : both groups of patients with *f*-ILD *vs* healthy controls (main effect of group).

Exercise times (i.e. 20% to 100% of exercise duration) correspond to an absolute work rate of (mean  $\pm$  SD) 24  $\pm$  8, 44  $\pm$  9, 65  $\pm$  14, 86  $\pm$  17 and 110  $\pm$  21 W in controls, 15  $\pm$  0, 32  $\pm$  7, 50  $\pm$  12, 67  $\pm$  14 and 82  $\pm$  16 W in patients with no significant cerebral deoxygenation and 15  $\pm$  6, 29  $\pm$  11, 44  $\pm$  16, 58  $\pm$  20 and 71  $\pm$  26 W in those presenting with significant cerebral deoxygenation, respectively.

**Figure 2.** Changes in ( $\Delta$ ) prefrontal cortex oxy- (HbO<sub>2</sub>, panel a), deoxy- (HHb, panel b) and total (HbTot, panel c) hemoglobin concentration as a function of exercise time during incremental cycling in healthy controls and patients with fibrotic interstitial lung disease (*f*-ILD) who presented (+) or not (-) with significant cerebral deoxygenation.

Data are mean  $\pm$  SD and are slightly shifted at each exercise time to avoid overlap. \*  $p < 0.05$  : patients with *f*-ILD *vs* healthy controls; †  $p < 0.05$  : patients with *f*-ILD showing *vs* showing no cerebral deoxygenation for  $\Delta$  HbO<sub>2</sub>, HHb or HbTot at a specific exercise time.

Exercise times (i.e. 20% to 100% of exercise duration) correspond to an absolute work rate of (mean  $\pm$  SD) 24  $\pm$  8, 44  $\pm$  9, 65  $\pm$  14, 86  $\pm$  17 and 110  $\pm$  21 W in controls, 15  $\pm$  0, 32  $\pm$  7, 50  $\pm$  12, 67  $\pm$  14 and 82  $\pm$  16 W in patients with no significant cerebral deoxygenation and 15  $\pm$  6, 29  $\pm$  11, 44  $\pm$  16, 58  $\pm$  20 and 71  $\pm$  26 W in those presenting with significant cerebral deoxygenation, respectively.

**Figure 3.** Changes in ( $\Delta$ ) oxygen saturation by pulse oximetry ( $\text{SpO}_2$ ) and cerebral tissue saturation (TSI) as a function of exercise time during incremental cycling in healthy controls and patients with fibrotic interstitial lung disease (*f*-ILD) who presented (+) or not (-) with significant cerebral deoxygenation.

Data are mean  $\pm$  SD and are slightly shifted at each exercise time to avoid overlap. Dashed line indicates the threshold for cerebral deoxygenation defined as a  $\geq 4\%$  drop in cerebral TSI during exercise. \*  $p < 0.05$  : patients with *f*-ILD *vs* healthy controls; †  $p < 0.05$  : patients with *f*-ILD showing *vs* showing no cerebral deoxygenation for  $\Delta \text{SpO}_2$  or  $\Delta \text{TSI}$  at a specific exercise time.

Exercise times (i.e. 20% to 100% of exercise duration) correspond to an absolute work rate of (mean  $\pm$  SD) 24  $\pm$  8, 44  $\pm$  9, 65  $\pm$  14, 86  $\pm$  17 and 110  $\pm$  21 W in controls, 15  $\pm$  0, 32  $\pm$  7, 50  $\pm$  12, 67  $\pm$  14 and 82  $\pm$  16 W in patients with no significant cerebral deoxygenation and 15  $\pm$  6, 29  $\pm$  11, 44  $\pm$  16, 58  $\pm$  20 and 71  $\pm$  26 W in those presenting with significant cerebral deoxygenation, respectively.

**Figure 4.** Relationship between changes from rest to peak exercise ( $\Delta$ ) in cerebral tissue saturation index and  $\Delta \text{O}_2$  saturation by pulse oximetry ( $\Delta \text{SpO}_2$ ) in patients with fibrotic interstitial lung disease who presented (+) or not (-) with significant cerebral deoxygenation.



Dashed line indicates the threshold for cerebral deoxygenation defined as a  $\geq 4\%$  drop in cerebral tissue saturation index during exercise.




**Figure 5.** Relationship between changes from rest to peak exercise ( $\Delta$ ) in cerebral tissue saturation index and exercise tolerance (peak  $\text{O}_2$  uptake, % predicted) in patients with fibrotic interstitial lung disease who presented (+) or not (-) with significant cerebral deoxygenation.






Dashed line indicates the threshold for cerebral deoxygenation defined as a  $\geq 4\%$  drop in cerebral tissue saturation index during exercise.

- Healthy controls ○
- f*-ILD (-) cerebral deoxygenation ●
- f*-ILD (+) cerebral deoxygenation ●









Cerebral deoxygenation  $\left\{ \begin{array}{l} \circ (-) \\ \bullet (+) \end{array} \right.$

